These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29066728)

  • 1. Ghrelin rescues skeletal muscle catabolic profile in the R6/2 mouse model of Huntington's disease.
    Sjögren M; Duarte AI; McCourt AC; Shcherbina L; Wierup N; Björkqvist M
    Sci Rep; 2017 Oct; 7(1):13896. PubMed ID: 29066728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Therapy with Liraglutide and Ghrelin Promotes Brain and Peripheral Energy Metabolism in the R6/2 Mouse Model of Huntington's Disease.
    Duarte AI; Sjögren M; Santos MS; Oliveira CR; Moreira PI; Björkqvist M
    Sci Rep; 2018 Jun; 8(1):8961. PubMed ID: 29895889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease.
    She P; Zhang Z; Marchionini D; Diaz WC; Jetton TJ; Kimball SR; Vary TC; Lang CH; Lynch CJ
    Am J Physiol Endocrinol Metab; 2011 Jul; 301(1):E49-61. PubMed ID: 21505144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ghrelin-mediated improvements in the metabolic phenotype in the R6/2 mouse model of Huntington's disease.
    Rudenko O; Springer C; Skov LJ; Madsen AN; Hasholt L; Nørremølle A; Holst B
    J Neuroendocrinol; 2019 Jul; 31(7):e12699. PubMed ID: 30776164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. White Adipose Tissue Browning in the R6/2 Mouse Model of Huntington's Disease.
    McCourt AC; Jakobsson L; Larsson S; Holm C; Piel S; Elmér E; Björkqvist M
    PLoS One; 2016; 11(8):e0159870. PubMed ID: 27486903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal muscle atrophy in R6/2 mice - altered circulating skeletal muscle markers and gene expression profile changes.
    Magnusson-Lind A; Davidsson M; Silajdžić E; Hansen C; McCourt AC; Tabrizi SJ; Björkqvist M
    J Huntingtons Dis; 2014; 3(1):13-24. PubMed ID: 25062762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leptin deficiency reverses high metabolic state and weight loss without affecting central pathology in the R6/2 mouse model of Huntington's disease.
    Sjögren M; Soylu-Kucharz R; Dandunna U; Stan TL; Cavalera M; Sandelius Å; Zetterberg H; Björkqvist M
    Neurobiol Dis; 2019 Dec; 132():104560. PubMed ID: 31419548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive Cl- channel defects reveal disrupted skeletal muscle maturation in R6/2 Huntington's mice.
    Miranda DR; Wong M; Romer SH; McKee C; Garza-Vasquez G; Medina AC; Bahn V; Steele AD; Talmadge RJ; Voss AA
    J Gen Physiol; 2017 Jan; 149(1):55-74. PubMed ID: 27899419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
    Wade A; Jacobs P; Morton AJ
    Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice.
    Bondulich MK; Jolinon N; Osborne GF; Smith EJ; Rattray I; Neueder A; Sathasivam K; Ahmed M; Ali N; Benjamin AC; Chang X; Dick JRT; Ellis M; Franklin SA; Goodwin D; Inuabasi L; Lazell H; Lehar A; Richard-Londt A; Rosinski J; Smith DL; Wood T; Tabrizi SJ; Brandner S; Greensmith L; Howland D; Munoz-Sanjuan I; Lee SJ; Bates GP
    Sci Rep; 2017 Oct; 7(1):14275. PubMed ID: 29079832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy.
    Mielcarek M; Toczek M; Smeets CJ; Franklin SA; Bondulich MK; Jolinon N; Muller T; Ahmed M; Dick JR; Piotrowska I; Greensmith L; Smolenski RT; Bates GP
    PLoS Genet; 2015 Mar; 11(3):e1005021. PubMed ID: 25748626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.
    Ribchester RR; Thomson D; Wood NI; Hinks T; Gillingwater TH; Wishart TM; Court FA; Morton AJ
    Eur J Neurosci; 2004 Dec; 20(11):3092-114. PubMed ID: 15579164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease.
    Martin B; Golden E; Carlson OD; Pistell P; Zhou J; Kim W; Frank BP; Thomas S; Chadwick WA; Greig NH; Bates GP; Sathasivam K; Bernier M; Maudsley S; Mattson MP; Egan JM
    Diabetes; 2009 Feb; 58(2):318-28. PubMed ID: 18984744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ghrelin improves body weight loss and skeletal muscle catabolism associated with angiotensin II-induced cachexia in mice.
    Sugiyama M; Yamaki A; Furuya M; Inomata N; Minamitake Y; Ohsuye K; Kangawa K
    Regul Pept; 2012 Oct; 178(1-3):21-8. PubMed ID: 22750276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficits in spermatogenesis but not neurogenesis are alleviated by chronic testosterone therapy in R6/1 Huntington's disease mice.
    Hannan AJ; Ransome MI
    J Neuroendocrinol; 2012 Feb; 24(2):341-56. PubMed ID: 21988129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced cerebral branched-chain amino acid metabolism in R6/2 mouse model of Huntington's disease.
    Andersen JV; Skotte NH; Aldana BI; Nørremølle A; Waagepetersen HS
    Cell Mol Life Sci; 2019 Jun; 76(12):2449-2461. PubMed ID: 30830240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington's Disease.
    Tomczyk M; Braczko A; Mierzejewska P; Podlacha M; Krol O; Jablonska P; Jedrzejewska A; Pierzynowska K; Wegrzyn G; Slominska EM; Smolenski RT
    Cells; 2022 Aug; 11(17):. PubMed ID: 36078070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease.
    Popovic V; Svetel M; Djurovic M; Petrovic S; Doknic M; Pekic S; Miljic D; Milic N; Glodic J; Dieguez C; Casanueva FF; Kostic V
    Eur J Endocrinol; 2004 Oct; 151(4):451-5. PubMed ID: 15476444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.